Suivant

Lecture automatique

Peptide Receptor Radionuclide Therapy (PRRT)

3 Vues • 07/09/23
Partager
Intégrer
administrator
administrator
Les abonnés
0

One of the most significant treatment options for neuroendocrine cancer patients became available with the 2018 FDA approval of Lutathera®, the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT).

NET experts Dr. Emily Bergsland, Dr. Pamela Kunz, Dr. Erik Mittra and Dr.
Jonathan Strosberg describe the treatment, how it works, and the benefits for patients.

What do physicians look forward to in the future for PRRT?

Montre plus
0 commentaires sort Trier par
Commentaires de Facebook

Suivant

Lecture automatique